NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31

NEOGENOMICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026

$16.42−0.23 (-1.38%)

Close on Oct 19, 2026

Market cap: $2.15B
P/E (TTM): –
Dividend yield: –

Dividends

Neogenomics has not reported a dividend

No dividend per share appears in Neogenomics's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Neogenomics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEO.

Revenue growth11.2% · median 6.8%

Gross margin43.9% · median 61.0%

Operating margin-8.9% · median 17.9%

Net margin-6.8% · median 16.1%

Company	Revenue	Growth
ULS	$3.15B	+6.6%
MEDP	$2.78B	+24.7%
NEO	$766.30M	+11.2%
VCYT	$561.90M	+17.3%
CSTL	$357.28M	+3.2%
FLGT	$323.93M	+6.8%

Company

Next earnings (est.): Oct 27, 2026, before open
Exchange: Nasdaq
Industry: Services-Testing Laboratories
Fiscal year ends: December 31
Employees: 2,500
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1077183

Advertisement
300 × 250